文献速递免疫规划

2017年美国13-17岁青少年国家、地区、州及部分地方疫苗接种覆盖率

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2018-08-24

CDC分析2017年全国青少年免疫调查(NIS-Teen)中20,949名13-17岁青少年数据。2016至2017年,≥1剂HPV疫苗覆盖率从60.4%升至65.5%,≥1剂MenACWY从82.2%升至85.1%,≥2剂MenACWY从39.1%升至44.3%;Tdap稳定在88.7%。2017年HPV疫苗系列完成率(HPV UTD)为48.6%,高于2016年的43.4%。

要点

  • 2017年13-17岁青少年≥1剂HPV疫苗覆盖率为65.5%,较2016年的60.4%上升。
  • 2017年≥1剂MenACWY覆盖率为85.1%,≥2剂为44.3%,均较2016年上升。
  • 2017年HPV疫苗系列完成率(HPV UTD)为48.6%,高于2016年的43.4%。

核心结论

  • 尽管HPV疫苗启动接种率仍低于MenACWY和Tdap,但自2013年以来HPV疫苗覆盖率年均增加5.1个百分点,持续针对未接种青少年并消除错失接种机会的努力可能使HPV疫苗覆盖率达到其他常规推荐青少年疫苗的水平。

研究设计与样本

  • CDC分析了2017年全国青少年免疫调查(NIS-Teen)中20,949名13-17岁青少年的数据,以估计美国青少年疫苗接种覆盖率。

主要发现

  • 2016至2017年,≥1剂HPV疫苗覆盖率从60.4%升至65.5%,≥1剂MenACWY从82.2%升至85.1%,≥2剂MenACWY从39.1%升至44.3%。
  • Tdap覆盖率保持稳定在88.7%。
  • 2017年HPV疫苗系列完成率(HPV UTD)为48.6%,2016年为43.4%。
  • 按时接种(13岁前接受≥2或≥3剂HPV疫苗)也有所增加。
  • 2017年,居住于非大都市统计区(non-MSA)的青少年≥1剂HPV疫苗接种覆盖率(59.3%)低于居住于MSA主要城市的青少年(70.1%)。

关键数值与推荐

  • ACIP推荐11-12岁儿童常规接种HPV疫苗、四价脑膜炎球菌结合疫苗(MenACWY)和破伤风类毒素、减量白喉类毒素及无细胞百日咳疫苗(Tdap)。
  • ACIP推荐16岁时接种MenACWY加强剂,并对乙肝疫苗(HepB)、麻疹-腮腺炎-风疹疫苗(MMR)和水痘疫苗(VAR)童年接种未及时完成(UTD)的青少年进行补种。
  • ACIP还推荐临床医生可为16-23岁青少年和年轻成人接种B群脑膜炎球菌疫苗(MenB)系列,首选年龄为16-18岁。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of persons aged 11-12 years with human papillomavirus (HPV) vaccine, quadrivalent meningococcal conjugate vaccine (MenACWY), and tetanus and reduced diphtheria toxoids and acellular pertussis vaccine (Tdap). A booster dose of MenACWY is recommended at age 16 years (1), and catch-up vaccination is recommended for hepatitis B vaccine (HepB), measles, mumps, and rubella vaccine (MMR), and varicella vaccine (VAR) for adolescents whose childhood vaccinations are not up to date (UTD) (1). ACIP also recommends that clinicians may administer a serogroup B meningococcal vaccine (MenB) series to adolescents and young adults aged 16-23 years, with a preferred age of 16-18 years (2). To estimate U.S. adolescent vaccination coverage, CDC analyzed data from the 2017 National Immunization Survey-Teen (NIS-Teen) for 20,949 adolescents aged 13-17 years.* During 2016-2017, coverage increased for ≥1 dose of HPV vaccine (from 60.4% to 65.5%), ≥1 dose of MenACWY (82.2% to 85.1%), and ≥2 doses of MenACWY (39.1% to 44.3%). Coverage with Tdap remained stable at 88.7%. In 2017, 48.6% of adolescents were UTD with the HPV vaccine series (HPV UTD) compared with 43.4% in 2016.† On-time vaccination (receipt of ≥2 or ≥3 doses of HPV vaccine by age 13 years) also increased. As in 2016, ≥1-dose HPV vaccination coverage was lower among adolescents living in nonmetropolitan statistical areas (MSAs) (59.3%) than among those living in MSA principal cities (70.1%).§ Although HPV vaccination initiation remains lower than coverage with MenACWY and Tdap, HPV vaccination coverage has increased an average of 5.1 percentage points annually since 2013, indicating that continued efforts to target unvaccinated teens and eliminate missed vaccination opportunities might lead to HPV vaccination coverage levels comparable to those of other routinely recommended adolescent vaccines.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Walker TY, Elam-Evans LD, Yankey D, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017. MMWR Morb Mortal Wkly Rep. 2018. PMID: 30138305. doi:10.15585/mmwr.mm6733a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。